In September 2024, the Company announced a plan to reprioritize research and development activities to focus on advancing pociredir for the treatment of sickle cell disease, novel therapeutic agents for the treatment of DBA, and the Company's early discovery programs. The plan reduced the Company’s workforce from 80 to 51 full-time employees, including a reduction of positions across both research and development and general and administrative functions. During the year ended December 31, 2024, the Company recorded aggregate restructuring charges of $2.1 million related to severance and other employee-related costs, all of which were paid during the year ended December 31, 2024.


Accrued restructuring charges as of December 31, 2023	$	—
Restructuring charges incurred during the period		2,063
Amounts paid during the period		(1,686	)
Accrued restructuring charges as of December 31, 2024	$	377